SynGenis
PrivateLast Round
Growth Equity
Jul 12, 2026
Total Funding Raised
$2.78M
Company Overview
SynGenis operates in Healthcare & Life Sciences and is based in Bentley. Its latest recorded funding round was a Growth Equity round in July 2026.
SynGenis is a biotechnology company that specializes in the production and supply of high-quality oligonucleotides for diagnostic and therapeutic applications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Pharma Supply Chain, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SynGenis Comparables
Compare SynGenis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Synoligo Biotechnologies | 83% | |
| Messenger Bio | 74% | |
| Danaher | 72% |
For institutional investors. Book with your work email.
SynGenis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Growth Equity | Jul 12, 2026 | ||||
| Seed | Mar 1, 2021 |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 25, 2026
Grew 63% QoQ, from 8 to 13 employees.
- Apr 11, 2026
Grew 71% QoQ, from 7 to 12 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 24, 2026
In Aug '26, SynGenis Pty Ltd is developing a second artificial intelligence engine designed to simulate clinical trials before patients enroll.
- receives_financingAug 24, 2026
On Aug 25th '26, Australian biotechnology company SynGenis Pty Ltd receives a $363K non-dilutive R&D tax refund under the Federal Government’s R&D Tax Incentive to support its RNA and DNA programs, laboratory capability, and manufacturing expansion.
- invests_into_assetsAug 24, 2026
SynGenis Pty Ltd plans to invest in construction of a Good Manufacturing Practice (GMP) facility that provides clinical-grade production for material used in human clinical trials and is targeted to become operational in early 2027.
For institutional investors. Book with your work email.
SynGenis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about SynGenis's valuation, stock price, and market status.
Is SynGenis a public or private company?
SynGenis is a private company.
What is the current stock price of SynGenis?
SynGenis is a private company, so its shares have no public market price. Caplight tracks SynGenis's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SynGenis worth (valuation)?
Valuation information for SynGenis is not publicly available.
Can I buy SynGenis stock?
SynGenis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SynGenis's last funding round?
SynGenis's most recent funding round was Growth Equity on July 12, 2026.
Who are the main investors in SynGenis?
Investor information for SynGenis is not publicly disclosed.
Will SynGenis IPO soon?
No public IPO plans have been announced for SynGenis.
How can I track SynGenis secondary market activity?
Caplight tracks bids, offers, and trades in SynGenis's shares on secondary markets.